AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30389673 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive weight loss lifestyle intervention based on an energy-restricted Mediterranean diet, physical activity promotion, and behavioral support
Number of subjects: 626
Study 30389673 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive weight loss lifestyle intervention
Number of subjects: 626
Study 30596696 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness meditation app 'Headspace' (n = 38) for 10 or 30 days
Number of subjects: 74
Study 30596696 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control (n = 36)
Number of subjects: 74
Study 26208743 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized nutrition counseling with whey protein supplementation
Number of subjects: 48
Study 26208743 — intervention group
Group type: COMPARATOR
Intervention: Individualized nutrition counseling with a nonnutritive placebo
Number of subjects: 48
Study 26208743 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 48
Study 24645985 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine 5 mg/day
Number of subjects: 32
Study 24645985 — intervention group
Group type: EXPERIMENTAL
Intervention: Azelnidipine 16 mg/day
Number of subjects: 32
Study 22526165 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose multislice-CT (MSCT) screening with five annual screens and initial quit-smoking counseling
Number of subjects: 4052
Study 22526165 — intervention group
Group type: COMPARATOR
Intervention: Initial quit-smoking counseling and five annual questionnaire inquiries
Number of subjects: 4052
Study 20164484 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose platelet transfusion (1.1x10(11) platelets/m2)
Number of subjects: 1272
Study 20164484 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium-dose platelet transfusion (2.2x10(11) platelets/m2)
Number of subjects: 1272
Study 20164484 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose platelet transfusion (4.4x10(11) platelets/m2)
Number of subjects: 1272
Study 20164484 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose platelet transfusion
Number of subjects: 1272
Study 20164484 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet counts 5000 per cubic millimeter or lower
Number of subjects: 1272
Study 20164484 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet counts 6000 to 80,000 per cubic millimeter
Number of subjects: 1272
Study 17085532 — intervention group
Group type: EXPERIMENTAL
Intervention: Resynchronisation (atrio-biventricular pacing)
Number of subjects: 22
Study 17085532 — intervention group
Group type: COMPARATOR
Intervention: Native activation (left bundle branch block)
Number of subjects: 22
Study 15967851 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasugrel
Number of subjects: 904
Study 15967851 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 904
Study 12417540 — intervention group
Group type: EXPERIMENTAL
Intervention: TF-positive microparticles in patients with type 2 diabetes
Number of subjects: 0
Study 12417540 — intervention group
Group type: EXPERIMENTAL
Intervention: TF-positive microparticles from T-helper cells in patients
Number of subjects: 0
Study 12417540 — intervention group
Group type: EXPERIMENTAL
Intervention: TF-positive microparticles from granulocytes in patients
Number of subjects: 0
Study 12417540 — intervention group
Group type: EXPERIMENTAL
Intervention: TF-positive microparticles from platelets in patients
Number of subjects: 0
Study 12417540 — intervention group
Group type: EXPERIMENTAL
Intervention: Microparticles from patients
Number of subjects: 0
Study 12417540 — intervention group
Group type: EXPERIMENTAL
Intervention: Microparticle numbers
Number of subjects: 0
Study 10360655 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracavitary chemotherapy (Group A, n = 13) with weekly injection of anticancer agents (cisplatin, mitomycin‐C, adriamycin, etc.)
Number of subjects: 41
Study 10360655 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunotherapy (Group B, n = 14) with weekly injection of streptococcal preparation OK‐432
Number of subjects: 41
Study 10360655 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunochemotherapy (Group C, n = 14) with ACAs and OK‐432
Number of subjects: 41
Study 10360655 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group A)
Number of subjects: 41
Study 8951750 — intervention group
Group type: EXPERIMENTAL
Intervention: Balloon Angioplasty (BA)
Number of subjects: 73
Study 8951750 — intervention group
Group type: COMPARATOR
Intervention: Simpson Directional Atherectomy (DA)
Number of subjects: 73
Study 1826806 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoximone 50 mg three times a day
Number of subjects: 164
Study 1826806 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoximone 100 mg three times a day
Number of subjects: 164
Study 1826806 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 164
Study 6293721 — intervention group
Group type: EXPERIMENTAL
Intervention: Ampicillin
Number of subjects: 195
Study 6293721 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefazolin
Number of subjects: 195
Study 6293721 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefotaxime
Number of subjects: 195
Study 6293721 — intervention group
Group type: COMPARATOR
Intervention: Placebo/Untreated
Number of subjects: 195
Study 31586784 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen 600 mg every 6 hours for 24 hours
Number of subjects: 43
Study 31586784 — intervention group
Group type: COMPARATOR
Intervention: Acetaminophen 650 mg every 6 hours for 24 hours
Number of subjects: 43
Study 27287561 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 PUFAs (1470mg docosahexaenoic acid and 147mg eicosapentaenoic acid per day)
Number of subjects: 83
Study 27287561 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 83
Study 25504295 — intervention group
Group type: EXPERIMENTAL
Intervention: eSTI screening using a home collection kit and an e-prescription for uncomplicated treatment
Number of subjects: 0
Study 25504295 — intervention group
Group type: COMPARATOR
Intervention: Standard clinic-based STI screening and treatment
Number of subjects: 0
Study 23814248 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic release
Number of subjects: 52
Study 23814248 — intervention group
Group type: COMPARATOR
Intervention: Open release
Number of subjects: 52
Study 21794114 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin-converting enzyme inhibitor (perindopril)
Number of subjects: 159
Study 21794114 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-blocker (bisoprolol)
Number of subjects: 159
Study 21794114 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 159
Study 19802538 — intervention group
Group type: EXPERIMENTAL
Intervention: Chinese herbal decoction
Number of subjects: 60
Study 19802538 — intervention group
Group type: COMPARATOR
Intervention: Intravenous dripping of ganciclovir 10 mg/kg per day
Number of subjects: 60
Study 17604311 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture for 6 weeks
Number of subjects: 181
Study 17604311 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiotherapy for 6 weeks
Number of subjects: 181
Study 17604311 — intervention group
Group type: COMPARATOR
Intervention: Standardized advice (Control)
Number of subjects: 181
Study 14687690 — intervention group
Group type: EXPERIMENTAL
Intervention: Naturalistic speech intervention (SI)
Number of subjects: 30
Study 14687690 — intervention group
Group type: COMPARATOR
Intervention: Phonologic speech intervention (SI)
Number of subjects: 30
Study 11793114 — intervention group
Group type: EXPERIMENTAL
Intervention: Circumcision after 6 months of observation (Group 1)
Number of subjects: 70
Study 11793114 — intervention group
Group type: EXPERIMENTAL
Intervention: Circumcision immediately after the first UTI (Group 2)
Number of subjects: 70
Study 11793114 — intervention group
Group type: COMPARATOR
Intervention: Uncircumcised group (Control)
Number of subjects: 70
Study 9597845 — intervention group
Group type: EXPERIMENTAL
Intervention: MOPP4-hot condition
Number of subjects: 14
Study 9597845 — intervention group
Group type: COMPARATOR
Intervention: MOPP0 uniform
Number of subjects: 14
Study 9597845 — intervention group
Group type: COMPARATOR
Intervention: MOPP4-cool condition
Number of subjects: 14
Study 7932240 — intervention group
Group type: EXPERIMENTAL
Intervention: Voluntary hyperventilation (VHV) to 15 or 25 mmHg for 3 or 6 min with mild hyperoxic gas mixtures (inspired PO2 approximately 250 mmHg)
Number of subjects: 9
Study 7932240 — intervention group
Group type: EXPERIMENTAL
Intervention: Voluntary hyperventilation (VHV)
Number of subjects: 9
Study 3280723 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical endurance training (2.5 h/week for 4 months)
Number of subjects: 27
Study 31977625 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine with magnesium sulfate
Number of subjects: 120
Study 31977625 — intervention group
Group type: COMPARATOR
Intervention: Remifentanil
Number of subjects: 120
Study 31977625 — intervention group
Group type: COMPARATOR
Intervention: Magnesium sulfate
Number of subjects: 120
Study 29948444 — intervention group
Group type: EXPERIMENTAL
Intervention: LPD + KA (42 patients)
Number of subjects: 79
Study 29948444 — intervention group
Group type: COMPARATOR
Intervention: LPD alone (37 patients)
Number of subjects: 79
Study 28185808 — intervention group
Group type: EXPERIMENTAL
Intervention: Sled push at 75% body mass
Number of subjects: 20
Study 28185808 — intervention group
Group type: EXPERIMENTAL
Intervention: Sled push at 125% body mass
Number of subjects: 20
Study 25111385 — intervention group
Group type: COMPARATOR
Intervention: Open Prostatectomy (OP)
Number of subjects: 320
Study 25111385 — intervention group
Group type: COMPARATOR
Intervention: Bipolar Plasma Enucleation of the Prostate (BPEP)
Number of subjects: 320
Study 25111385 — intervention group
Group type: COMPARATOR
Intervention: Transurethral Resection in Saline (TURis)
Number of subjects: 320
Study 25111385 — intervention group
Group type: COMPARATOR
Intervention: Transurethral Vaporization in Saline (TUVis)
Number of subjects: 320
Study 24138710 — intervention group
Group type: EXPERIMENTAL
Intervention: High-flow nasal cannula oxygen (HFNC)
Number of subjects: 220
Study 24138710 — intervention group
Group type: COMPARATOR
Intervention: Conventional oxygen therapy
Number of subjects: 220
Study 21419684 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-discharge pharmaceutical care programme (verbal and written information about treatment)
Number of subjects: 59
Study 21419684 — intervention group
Group type: COMPARATOR
Intervention: Standard discharge without additional information (control group)
Number of subjects: 59
Study 18328930 — intervention group
Group type: EXPERIMENTAL
Intervention: Doubling of cash transfers
Number of subjects: 2449
Study 16427182 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% NaOCl/ 30 min + EnForce
Number of subjects: 40
Study 16427182 — intervention group
Group type: EXPERIMENTAL
Intervention: without 1% NaOCl + EnForce
Number of subjects: 40
Study 16427182 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% NaOCl/ 30 min + Rely X
Number of subjects: 40
Study 16427182 — intervention group
Group type: EXPERIMENTAL
Intervention: without 1% NaOCl + Rely X
Number of subjects: 40
Study 16427182 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 40
Study 14632812 — intervention group
Group type: EXPERIMENTAL
Intervention: Dysport (283.7 U)
Number of subjects: 8
Study 14632812 — intervention group
Group type: COMPARATOR
Intervention: Botox (69.3 U)
Number of subjects: 8
Study 14632812 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-evaluation for Dysport
Number of subjects: 8
Study 14632812 — intervention group
Group type: COMPARATOR
Intervention: Self-evaluation for Botox
Number of subjects: 8
Study 14632812 — intervention group
Group type: EXPERIMENTAL
Intervention: Local side effects for Dysport
Number of subjects: 8
Study 14632812 — intervention group
Group type: COMPARATOR
Intervention: Local side effects for Botox
Number of subjects: 8
Study 14632812 — intervention group
Group type: EXPERIMENTAL
Intervention: Duration of positive effect for Dysport
Number of subjects: 8
Study 14632812 — intervention group
Group type: COMPARATOR
Intervention: Duration of positive effect for Botox
Number of subjects: 8
Study 11228061 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH agonist (n = 12)
Number of subjects: 35
Study 11228061 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH agonist plus COC (n = 12)
Number of subjects: 35
Study 11228061 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH agonist plus flutamide (n = 11)
Number of subjects: 35
Study 11228061 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (GnRH agonist, GnRH agonist plus COC, GnRH agonist plus flutamide)
Number of subjects: 35
Study 8873738 — intervention group
Group type: EXPERIMENTAL
Intervention: Epsilon-aminocaproic acid
Number of subjects: 103
Study 8873738 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 103
Study 2064943 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical PUVA
Number of subjects: 27
Study 2064943 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 6359490 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g metronidazole
Number of subjects: 132
Study 6359490 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 g metronidazole
Number of subjects: 132
Study 3903907 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunotherapy
Number of subjects: 0
Study 3903907 — intervention group
Group type: EXPERIMENTAL
Intervention: Disease stage
Number of subjects: 0
Study 31500524 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose intravenous ET-1 infusion
Number of subjects: 14
Study 31500524 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 14
Study 30192328 — intervention group
Group type: EXPERIMENTAL
Intervention: Liposomal bupivacaine transversus abdominis plane block
Number of subjects: 200
Study 30192328 — intervention group
Group type: COMPARATOR
Intervention: Epidural analgesia
Number of subjects: 200
Study 28116433 — intervention group
Group type: EXPERIMENTAL
Intervention: Lauromacrogol combined with pingyangmycin injection
Number of subjects: 120
Study 28116433 — intervention group
Group type: COMPARATOR
Intervention: Pingyangmycin injection
Number of subjects: 120
Study 24261927 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfredson eccentric heel-drop protocol (standard group, n = 15)
Number of subjects: 28
Study 24261927 — intervention group
Group type: EXPERIMENTAL
Intervention: Do-as-tolerated protocol (do as tolerated group, n = 13)
Number of subjects: 28
Study 24261927 — intervention group
Group type: COMPARATOR
Intervention: Comparison between groups at week 3
Number of subjects: 28
Study 24261927 — intervention group
Group type: COMPARATOR
Intervention: Comparison between groups at week 6
Number of subjects: 28
Study 24261927 — intervention group
Group type: COMPARATOR
Intervention: Treatment satisfaction at week 6
Number of subjects: 28
Study 22122475 — intervention group
Group type: EXPERIMENTAL
Intervention: PALS I-II
Number of subjects: 0
Study 22122475 — intervention group
Group type: EXPERIMENTAL
Intervention: PALS I-DAS II
Number of subjects: 0
Study 22122475 — intervention group
Group type: EXPERIMENTAL
Intervention: DAS I-PALS II
Number of subjects: 0
Study 22122475 — intervention group
Group type: COMPARATOR
Intervention: DAS I-II
Number of subjects: 0
Study 19800931 — intervention group
Group type: EXPERIMENTAL
Intervention: Vicoprofen (hydrocodone bitartrate 7.5mg with Ibuprofen 200mg)
Number of subjects: 36
Study 19800931 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen (200mg)
Number of subjects: 36
Study 19800931 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 19164820 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower-intensity resistance training (RTL, n = 8)
Number of subjects: 20
Study 19164820 — intervention group
Group type: COMPARATOR
Intervention: Moderate-intensity aerobic training (ATM, n = 12)
Number of subjects: 20
Study 15718045 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary artery disease (CAD) subjects
Number of subjects: 20
Study 15718045 — intervention group
Group type: COMPARATOR
Intervention: Healthy matched control subjects
Number of subjects: 20
Study 14728543 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated decision support
Number of subjects: 0
Study 14728543 — intervention group
Group type: EXPERIMENTAL
Intervention: On-demand decision support
Number of subjects: 0
Study 14728543 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 10570335 — intervention group
Group type: COMPARATOR
Intervention: Standard catheter
Number of subjects: 47
Study 10570335 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard/wire-guided sphincterotome
Number of subjects: 47
Study 8931608 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction chemotherapy plus radiotherapy
Number of subjects: 0
Study 8931608 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery plus adjuvant chemotherapy
Number of subjects: 0
Study 1881831 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil (3 x 120 mg/24 hr)
Number of subjects: 15
Study 1881831 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 6137859 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurazepam 30 mg, administered at night
Number of subjects: 0
Study 6137859 — intervention group
Group type: EXPERIMENTAL
Intervention: Triazolam 0.5 mg, administered at night
Number of subjects: 0
Study 6137859 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurazepam 15 mg, administered in the morning
Number of subjects: 0
Study 6137859 — intervention group
Group type: EXPERIMENTAL
Intervention: Triazolam 0.25 mg, administered in the morning
Number of subjects: 0
Study 6137859 — intervention group
Group type: COMPARATOR
Intervention: Placebo, administered in the morning
Number of subjects: 0
Study 31143442 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-day (single dose) cefazolin
Number of subjects: 0
Study 31143442 — intervention group
Group type: COMPARATOR
Intervention: 2-day cefazolin
Number of subjects: 0
Study 30226448 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitting with 3 min bouts of light‐intensity exercise while standing every 30 min
Number of subjects: 19
Study 30226448 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitting with 3 min of walking every 30 min
Number of subjects: 19
Study 30226448 — intervention group
Group type: COMPARATOR
Intervention: Sitting for 8 h uninterrupted
Number of subjects: 19
Study 27541162 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-expanding TAVR
Number of subjects: 383
Study 27541162 — intervention group
Group type: COMPARATOR
Intervention: SAVR
Number of subjects: 383
Study 23904473 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab-SC 162 mg weekly
Number of subjects: 1262
Study 23904473 — intervention group
Group type: COMPARATOR
Intervention: Tocilizumab-IV 8 mg/kg every 4 weeks
Number of subjects: 1262
Study 23904473 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab-SC
Number of subjects: 1262
Study 23904473 — intervention group
Group type: COMPARATOR
Intervention: Tocilizumab-IV
Number of subjects: 1262
Study 22512898 — intervention group
Group type: EXPERIMENTAL
Intervention: 54 mg OROS-MPH
Number of subjects: 24
Study 22512898 — intervention group
Group type: EXPERIMENTAL
Intervention: 54 mg MPH ER-C
Number of subjects: 24
Study 22512898 — intervention group
Group type: COMPARATOR
Intervention: 60 mg MPH-SR
Number of subjects: 24
Study 22512898 — intervention group
Group type: EXPERIMENTAL
Intervention: MPH ER-C
Number of subjects: 24
Study 20932900 — intervention group
Group type: EXPERIMENTAL
Intervention: Monodisperse salbutamol sulphate aerosols of 1.5, 3 and 6 μm mass median aerodynamic diameter in a cumulative dosing schedule of 10, 20, 40 and 100 μg
Number of subjects: 18
Study 20932900 — intervention group
Group type: EXPERIMENTAL
Intervention: Monodisperse salbutamol sulphate aerosols
Number of subjects: 18
Study 17006439 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticotropin-releasing hormone (CRH) 1 microg/kg
Number of subjects: 12
Study 17006439 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 16130428 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol
Number of subjects: 869
Study 16130428 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenoterol
Number of subjects: 869
Study 16130428 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium bromide
Number of subjects: 869
Study 16130428 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed combination of phenoterol and ipratropium bromide
Number of subjects: 869
Study 16130428 — intervention group
Group type: EXPERIMENTAL
Intervention: Bronchodilators (general)
Number of subjects: 869
Study 16130428 — intervention group
Group type: EXPERIMENTAL
Intervention: ICS-treated patients
Number of subjects: 869
Study 16130428 — intervention group
Group type: EXPERIMENTAL
Intervention: ICS-untreated patients
Number of subjects: 869
Study 16130428 — intervention group
Group type: COMPARATOR
Intervention: Bronchodilators
Number of subjects: 869
Study 11495172 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive‐behavioral/skill training therapy (CBT)
Number of subjects: 677
Study 11495172 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational interviewing/supportive (MIS) therapy
Number of subjects: 677
Study 11495172 — intervention group
Group type: COMPARATOR
Intervention: Brief intervention (BI) treatment
Number of subjects: 677
Study 9926240 — intervention group
Group type: EXPERIMENTAL
Intervention: Escalated BEACOPP
Number of subjects: 1300
Study 9926240 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline BEACOPP
Number of subjects: 1300
Study 9926240 — intervention group
Group type: COMPARATOR
Intervention: COPP/ABVD
Number of subjects: 1300
Study 7848492 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 20
Study 7848492 — intervention group
Group type: COMPARATOR
Intervention: Methohexitone
Number of subjects: 20
Study 3178974 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary closure (sutured wounds)
Number of subjects: 96
Study 3178974 — intervention group
Group type: COMPARATOR
Intervention: Leaving the wound open (unsutured wounds)
Number of subjects: 96
Study 3178974 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall infection rate
Number of subjects: 96
Study 3178974 — intervention group
Group type: EXPERIMENTAL
Intervention: Infection rate in hand wounds
Number of subjects: 96
Study 1180578 — intervention group
Group type: EXPERIMENTAL
Intervention: End-to-end jejunoileal bypass (30 cm jejunum to 15 cm ileum)
Number of subjects: 150